Reported Late Thursday, Vicarious Surgical Completes Public Demonstration Of Beta 2 Surgical Robotic System
Vicarious Surgical Inc. ("Vicarious Surgical" or the "Company"), a next-generation robotics company seeking to improve the cost, efficiency, and outcomes of surgical procedures, hosted the first
FDA Approves Gilead’s New HIV Treatment For Heavily Treated With Multi-Drug Resistant Patients
The FDA has approved Gilead Sciences Inc’s (NASDAQ:GILD) Sunlenca (lenacapavir), in combination with another antiretroviral (s) (ARV), for HIV-1 infection in…
‘Gemini Therapeutics Merger Company Disc Medicine Granted FDA Orphan Designation For Erythropoietic Protoporphyria Treatment’
https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=916222
Sunlenca Receives FDA Approval As A First-In-Class, Twice-Yearly Treatment Option For People Living With Multi-Drug Resistant HIV
– Sunlenca is the First and Only Approved Capsid Inhibitor-Based HIV Treatment Option –
– New Drug Application Approval Based on High Rates of Sustained Virologic Suppression in the
‘FYARRO, Sirolimus Protein-Bound Particles For Injectable Suspension, Albumin-Bound, FDA Approved For Treatment Of Locally Advanced Unresectable Or Metastatic Malignant Perivascular Epithelioid Cell Tumor, Available At Biologics By McKesson’
https://www.mckesson.com/About-McKesson/Newsroom/Press-Releases/2022/FYARRO-FDA-Approved-Treatment-Advanced-Unresectable-Metastatic-Malignant-Perivascular-Epithelioid-Cell-Tumor/
Biologics by McKesson, an independent
Akebia Therapeutics Receives Interim Response To Appeal For Vadadustat For Treatment Of Anemia Due To Chronic Kidney Disease From FDA
Akebia met with the FDA in November to discuss its appeal and subsequently received a request for additional clarifying information from the Office of New Drugs, Center for Drug Evaluation and Research, which is deciding
Armata Pharmaceuticals Announces Completion Of Its Phase 1b/2a ‘SWARM-P.a.’ Study Of Inhaled AP-PA02 In Cystic Fibrosis Subjects With Chronic Pulmonary Pseudomonas aeruginosa Infection
Armata Pharmaceuticals, Inc. (NYSE:ARMP) ("Armata" or the "Company"), a biotechnology company focused on pathogen-specific bacteriophage therapeutics for antibiotic-resistant and difficult-to-treat
BridgeBio Pharma Initiates CALIBRATE, A Pivotal Phase 3 Study Of Encaleret In Autosomal Dominant Hypocalcemia Type 1
- The CALIBRATE Phase 3 study design incorporates feedback from global regulatory agencies and will compare the effects of encaleret to standard of care on blood and urinary calcium concentrations over a 24 week